Related Experiment Videos
Evaluating reference-based pricing: initial findings and prospects
L Narine1, M Senathirajah, T Smith
1Department of Health Administration, University of Toronto, Ont. lutchmie.narine@utoronto.ca
Summary
Reference-based pricing in British Columbia (BC) initially reduced drug expenditures significantly. However, long-term success requires further research into health outcomes and broader impacts.
Area of Science:
- Health Economics
- Pharmaceutical Policy
- Public Health
Background:
- Reference-based pricing (RBP) is a policy tool to manage pharmaceutical spending.
- Several European countries and British Columbia (BC) have implemented RBP systems.
Purpose of the Study:
- To assess the preliminary impacts of BC's RBP policy on drug expenditures.
- To review international experiences with RBP.
Main Methods:
- Analysis of secondary utilization and cost data from BC.
- Review of previous studies on RBP in OECD countries.
Main Results:
- International RBP implementation showed temporary reductions in pharmaceutical expenditure growth.
- BC's RBP led to substantial initial declines in expenditures for referenced drug categories, from $42.0M to $23.7M annually.
Conclusions:
- Early data suggest BC's RBP is effective in reducing drug costs.
- Further comprehensive, longitudinal research is necessary to determine RBP's overall success, including its impact on health outcomes.